Shares of Tenax Therapeutics Inc. climbed 3.8% in premarket trading on Monday, extending gains tied to new clinical data presented at the European Society of Cardiology Congress 2026 in Munich.
The company’s experimental oral levosimendan therapy, TNX-103, demonstrated a significant reduction in NT-proBNP levels during a Late-Breaking Clinical Science session on August 29. The biomarker is an indicator of cardiac wall stress, suggesting potential efficacy in treating pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF), a condition for which no approved treatments currently exist.
The presentation was led by Professor Sanjiv Shah of Northwestern University, who highlighted the drug’s ability to address an unmet medical need. Tenax’s shares have traded near multi-month lows since initial data disclosures on August 10, but the latest findings appear to have reversed that trend.
Wall Street analysts at major firms initiated coverage with positive ratings, assigning price targets ranging from $35 to $40 per share. The company’s financial position remains robust, with approximately $118 million in cash reserves and a projected runway extending into the second quarter of 2028.
The stock’s movement occurred against a backdrop of slightly weaker U.S. equity futures, with the S&P 500, Dow Jones Industrial Average, and Nasdaq all trading modestly lower in premarket trading on August 31, 2026. Analysts attributed the volatility primarily to the clinical news rather than broader market conditions.
Tenax Therapeutics did not respond to requests for comment.
